Background and study aim: Ulcerative colitis (UC) and Crohn's disease (CD) are the common forms of inflammatory bowel disease (IBD). The etiology and pathogenesis are not fully understood yet. Many studies have been focused on adipokines in the pathogenesis of IBD. IBD is associated with alteration in fat distribution and development of white adipose tissue (WAT) hypertrophy in the mesentery. Most of adepokines are formed in WAT or in immune cells play an important role in IBD manifestations. The aim of this study was to evaluate the levels of resistin and visfatin in IBD patients before and after treatment. Patients and methods: 40 patients with IBD (15 patients with CD and 25 patients with UC) attended to Tropical Medicine and Internal Medicine Departments; Zagazig University Hospitals from March 2012 till December 2013 were included in this study. Serum levels of resistin and visfatin were measured before treatment and 3 months after treatment. Results : The mean serum levels of resistin in Crohn's disease ranged from 12.2+2 ng/ml to 9.0 + 4.0 (P= 0.1) and the mean serum levels of visfatin in Crohn's disease ranged from 5.6+4.6 ng/ml to 3.4+4.1 ng/ml (P= 0.04) before and after treatment respectively, and the mean serum levels of resistin in ulcerative colitis ranged from 11.2+2 ng/ml to 7.5+ 3.1 ng/ml (P= 0.039) and the mean serum levels of visfatin in ulcerative colitis ranged from 3.7+1.2 to 2.5+1.1 ng/ml (P= 0.004) before and after treatment respectively. Conclusion : The serum levels of resistin and visfatin decreased significantly after treatment induction for IBD so can be used as a marker for treatment success